| BIOGEN INC. DL -,0005 | 244.000 / -0.20% |
| Date/Time | 09/28 / 22:59 |
| Chg. / Chg.(%) | -0.500 / -0.20% |
| Bid | 244.000 |
| Ask | 245.050 |
| Open | 244.500 |
| Previous Close | 244.500 |
| High | 249.200 |
| Low | 242.750 |
| Volume [EUR] | - |
| Volume [Units] | |
| Price fixings | 7829 |
| ISIN | US09062X1037 |
| Security | IDP |
| Exchange | Lang & Schwarz |
| Type | Stock |
Other Exchanges
| Exchange | Last | Volume | |
|---|---|---|---|
| NASDAQ | 284.7100 |  |
785,411 |
| Cboe US | 284.77 | |
45,386 |
| IEX | 284.63 | |
25,068 |
| Moscow | 21,121.00 | 2,353 | |
| London Domes.. | 286.98 | |
868 |
| Xetra | 245.95 | |
610 |
| TradeGate | 246.050 | |
373 |
| Frankfurt | 245.7000 | |
100 |
| gettex | 244.950 | |
59 |
| Vienna Globa.. | 245.45 | |
35 |
| München | 249.65 | |
5 |
| Hamburg | 244.45 |  |
0 |
| Düsseldorf | 245.85 | |
0 |
| Berlin | 246.10 | |
0 |
| Hannover | 244.45 | |
0 |
| Stuttgart | 245.400 | |
0 |
| Quotrix | 245.0500 | |
|
| Lang & Schwa.. | 244.000 | |
|
| Mexico | 5,775.00 | |
167 |
News
- Biogen R&D Day to Provide Overview of Diversified Pipeline and Capabilities with Potential for Multiple Novel Therapies in Neuroscience
09/21/2021 / 14:30 - GlobeNewswire - FDA Approves Samsung Bioepis and Biogen’s BYOOVIZ™ (SB11), LUCENTIS® Biosimilar (ranibizumab-nuna)
09/20/2021 / 13:30 - GlobeNewswire - CHMP Recommends VUMERITY® (diroximel fumarate) for Approval in the European Union as a Treatment for Relapsing-Remitting Multiple Sclerosis
09/17/2021 / 15:09 - GlobeNewswire - Biogen Announces Positive Topline Results from Phase 2 CONVEY Study in Small Fiber Neuropathy
09/16/2021 / 13:30 - GlobeNewswire - Biogen Plans to Initiate Phase 3b Study Evaluating Potential Benefit of a Higher Dose of Nusinersen in Patients Previously Treated with Evrysdi® (risdiplam)
09/15/2021 / 13:30 - GlobeNewswire
Real-time